ClinicalTrials.gg

Program

TQD3606

A development code. Also written as “The injectable TQD3606”.

In Sino Biopharmaceutical's pipeline, 美罗培南阿维巴坦钠. Its studies are mostly in Infections, led by Sino Biopharmaceutical.

Furthest: phase 1, since Apr 1, 20222 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical20 open or runningphase 1since Apr 1, 2022Apr 1, 2022none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQD3606, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 1, 2022First study: phase 1 study in InfectionsFirst studyNCT05340530 · 56 enrolled · China
  2. Oct 31, 2024Phase 1 study in Resistant to Gram-positive, Gram-negative and Anaerobic BacteriaNCT06672276 · 32 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“美罗培南阿维巴坦钠”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06672276Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria · China1CompletedMay 6, 202532
NCT05340530Infections · China1UNKNOWNDec 202356

How it is read

Names in the registry

  • “TQD3606”, 1 entry
  • “The injectable TQD3606”, 1 entry

Codes read as this program: TQD3606.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.